

Ypsomed Ltd. (UK)
Blackwood Hall Business Park
North Duffield, Selby, N. Yorks, YO8 5DD / United Kingdom
www.ypsomed.co.uk

Ypsomed Holding AG
Brunnmattstrasse 6 / P.O. Box
3401 Burgdorf / Switzerland
www.ypsomed.com

MEDIA RELEASE

Ypsomed strengthens its European Diabetes Care sales organization by establishing a fully owned subsidiary in the United Kingdom

Burgdorf (Switzerland) / Selby (UK), 30th March 2010, 7:30am – Ypsomed Group today announced that it has established its fully owned subsidiary Ypsomed Ltd. in the United Kingdom with the goal to further strengthen its European Diabetes sales and marketing organization for its mylife™ Diabetescare range of products and services. Ypsomed Ltd. will acquire certain assets from its existing distributor as of April 1st, 2010, and market the mylife™ Penfine® pen needles, the mylife™ Pura™ blood glucose monitoring system and starting in June 2010 the mylife™ OmniPod® insulin patch pump, the world's first tubeless and easy-to-use insulin pump in the United Kingdom.

Introducing the full range of the mylife™ Diabetescare products and services to the United Kingdom

The newly appointed Country Manager of Ypsomed Ltd. in the United Kingdom, Matthew Bayliss-Binks, is extremely excited: "Ypsomed is known for its decade long diabetes competence and its comprehensive diabetes service portfolio. We are proud and highly motivated to introduce the full range of the mylife™ Diabetescare products and services to the UK market. Including the mylife™ Pura™ blood glucose monitoring system, the mylife™ Penfine® pen needles and later in the year the mylife™ Clickfine® AutoProtect™ safety pen needle for doctors' practices, nursing homes and hospitals. In addition, we will soon be launching the unique mylife™ OmniPod® insulin patch pump with no tubing and automated, virtually pain-free needle insertion which provides unprecedented freedom, comfort and ease in managing diabetes."

Expanding sales and marketing in a highly attractive diabetes market

Richard Fritschi, CEO of Ypsomed, adds, "Ypsomed has one of the largest independent European sales and marketing organisation focused on diabetes care. We are committed to strengthen our sales and marketing organisation with our fully owned subsidiary in the United Kingdom in addition to our existing subsidiaries in Germany, France, Switzerland, the Netherlands and Scandinavia as well as in India. The United Kingdom is the third largest diabetes market in Europe after Germany and France, growing annually at a two-digit percentage rate. It is our goal to increase our revenue share in this highly attractive market."

Further information is available from Daniel Kusio, Head of Investor & Public Relations at Ypsomed Holding AG. Phone +41 34 424 41 43 or +41 34 424 41 11. This media release with additional information is available in electronic form at www.ypsomed.com (www.ypsomed.com/en/company/123.html). Contact in the UK: Matthew Bayliss-Binks, Country Manager Ypsomed Ltd., Phone: +44 7769 144873

About Ypsomed

Ypsomed is a leading independent diabetes care specialist and technology provider of innovative injection systems for self-medication. Ypsomed emerged in 2003 from one of the two divisions of the well-known Disetronic Group and can draw on over 25 years of experience in diabetes care, insulin pumps as well as injection systems and pen needles for the treatment of diabetes, growth disorders, infertility and other therapeutic areas. Thanks to a broad-based technology platform and over 300 patent families, Ypsomed is widely regarded as the technology and innovation leader and therefore the preferred partner of pharmaceutical and biotech companies in the field of self-injection. Ypsomed has established itself as a leading supplier of branded, co-branded and OEM products to the retail and professional markets. With established partnerships with leading pharmaceutical and biotech companies, Ypsomed is committed to advancements in patient care. Ypsomed is headquartered in Burgdorf (Switzerland) and operates several manufacturing locations in Switzerland as well as a leading independent European sales and distribution network for diabetes care products and services. The Ypsomed Group has more than 1'200 employees.